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Abstract
Background: Programmed cell death 5 (PDCD5) was first identified as an apoptosis-promoting protein and
involved in some autoimmune diseases and inflammatory processes. Our previous study demonstrated greater
expression of serum PDCD5 in asthmatic patients than controls. This study aimed to further explore the significance
of PDCD5 in mice with induced allergic asthma.
Methods: We divided 16 female mice into 2 groups: control (n = 8) and allergen (ovalbumin, OVA)-challenged mice
(n = 8). The modified ovalbumin inhalation method was used to generate the allergic asthma mouse model, and
the impact of OVA was assessed by histology of lung tissue and morphometry. The number of cells in bronchoalveolar
lavage fluid (BALF) was detected. Pulmonary function was measured by pressure sensors. PDCD5 and active caspase-3
levels were detected.
Results: The expression of PDCD5 was higher with OVA challenge than for controls (p < 0.05). PDCD5 level was
correlated with number of inflammatory cells in BALF and lung function. Moreover, active caspase-3 level was
increased in the OVA-challenged mice (p < 0.001) and correlated with PDCD5 level (p = 0.000).
Conclusions: These data demonstrate an association between level of PDCD5 and asthma severity and indicate that
PDCD5 may play a role in allergic asthma.
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Background
Allergic asthma is a chronic inflammatory disorder of
the airways; many cells, such as lymphocytes, mast cells,
eosinophils, smooth muscle cells, and cellular elements,
contribute to its pathophysiological processes. The fre-
quent occurrence of injury and repair initiated by
chronic inflammation could lead to structural changes in
the airway, collectively termed airway remodeling, which
is characterized by epithelial injury, sub-epithelial fibro-
sis, enhanced deposition of extracellular matrix proteins,
goblet cells and mucous gland hypertrophy and in-
creased airway smooth muscle mass [1]. Airway inflam-
mation and remodeling are two characteristics of asthma
[2]. The development of chronic airway inflammation
depends on the continuous recruitment of inflammatory
cells and their subsequent activation. Duncan et al. dem-
onstrated that patients with mild asthma had a signifi-
cantly lower percentage of sputum eosinophils and a
significantly higher eosinophil apoptotic ratio (AR) than
those with moderate or chronic severe asthma [3]. In-
creasing evidence has shown that a dysregulation in pro-
grammed cell death mechanisms of both mobile and
resident cells of the airways may directly contribute to
the development of asthma as well as its clinical severity
[3–6].
Programmed cell death or apoptosis is a form of cellu-
lar suicide widely observed in nature. Duncan et al. dem-
onstrated a significant correlation of reduced apoptosis
in eosinophils present in induced sputum with asthma
severity [3]. Caspases are important regulators of apop-
tosis. Caspase-3 is considered the key executioner cas-
pase in apoptosis [7–9]. The level of apoptotic caspase-3
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protein was found increased in bronchial epithelial cells
or lung tissues in asthma [10–12]. In contrast, its level
was markedly decreased in pulmonary vascular smooth
muscle of an asthma model [13]. Apoptosis is also a cen-
tral and essential process in the resolution of inflamma-
tion. The resolution of eosinophilic inflammation of
asthma relies on corticosteroids. Steroids can induce
apoptosis of lung eosinophils and enhance the recogni-
tion and engulfment of apoptotic eosinophils by macro-
phages or bronchial epithelial cells [14]. However, the
regulation mechanism of apoptosis in asthma control is
not clear.
Programmed cell death 5 (PDCD5) was first identified
as an apoptosis-promoting protein [15]. It was associ-
ated with DNA damage-induced apoptosis by interacting
with the histone acetyltransferase Tip60 and was phos-
phorylated in vitro or in vivo by the multifunctional
kinase CK2 [16, 17]. Clinically, PDCD5 is involved in
some autoimmune diseases and inflammatory processes
such as lupus nephritis [18], rheumatoid arthritis [19],
osteoarthritis [20], hepatitis [21] and sepsis [22]. However,
few studies have focused on whether and how PDCD5 is
involved in asthma. We previously found serum PDCD5
level higher in patients with asthma than controls and
negatively correlated with several indexes of lung func-
tion [23].
Here we established a mouse model of allergic asthma




Chicken egg ovalbumin (OVA) and aluminium hydroxide
powder were from Sigma-Aldrich (St Louis, MO, USA).
Periodic acid-Schiff staining (PAS) and Masson’s tri-
chrome staining (Masson) kits were from Shanghai
Yuanye Bio-Technology. Mouse anti-PDCD5 monoclonal
antibody and the PDCD5 ELISA kit were gifts from Prof.
Yingyu Chen (Center for Human Disease Genomics,
Peking University, Beijing). Anti-active caspase 3 antibody
was from Abcam (Cambridge, MA, USA).
Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the US National Institutes of
Health. The protocol was approved by the Committee
on the Ethics of Animal Experiments of Peking University
Health Science Center (Permit No.: LA2011-062). All
surgery was performed with animals under urethane
anesthesia, and all efforts were made to minimize
suffering.
BALB/c mice (female, 6–8 weeks old) were obtained
from the Department of Laboratory Animal Science
(Peking University Health Science Center, Beijing). They
were kept under pathogen-free conditions and had free
access to food and water during experiments. Mice were
randomly divided into 2 groups (n = 8 each): control and
allergen (OVA)-challenged group.
Establishing allergic asthma mouse model
The modified OVA inhalation method was used to gen-
erate the allergic asthma mouse model as described [24].
Briefly, the protocol consisted of an intraperitoneal in-
jection of 20 μg OVA and 2.25 mg aluminum hydroxide
gel on day 1 and 14. On day 21, the mice were placed in
a plexiglass chamber (40 × 30 × 15 cm) connected to an
ultrasonic nebulizer (model YC-Y800, Yadu, Beijing) and
subjected to repeated bronchial allergen inhalation with
30 ml OVA (2.5% weight/volume diluted in sterile
physiological saline) for 30 min/day on 3 consecutive
Fig. 1 Clinicopathological indexes in mouse groups: control (n = 8)
and allergen (ovalbumin, OVA)-challenged mice (n = 8). a Lung
function. b Counts of inflammatory cells in bronchoalveolar fluid
(BALF). Data are mean ± SD. *P < 0.05 compared with control. PIF,
peak inspiratory flow; PEF, peak expiratory flow; IP, intra-airway
pressure; IP slope, maximum rising slope of IP
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days/week for up to 8 weeks. Control animals received
only saline. Mice were killed 24 h after the last exposure.
Respiratory function measurement
The mice were anesthetized with 10% urethane injected
intraperitoneally and were intubated endotracheally by
use of a trocar. Respiratory function was detected by
using an animal ventilator (AD Instruments, Australia)
connected to a pressure sensor. A “Y”-type trachea tube
connected to flow sensors and pressure sensors was
inserted into the trachea. A ventilator was connected to
a flow sensor. The tidal volume was 10 mL/kg and the
respiratory rate was 60 times/min. The Powerlab multi-
lead physical instrument was connected to flow and
pressure sensors. The peak inspiratory flow (PIF),
peak expiratory flow (PEF), intra-airway pressure (IP)
and maximum rising slope of IP (IP slope) were
measured, and data were analyzed by using Chart 4.1 (AD
Instruments, Australia).
Bronchoalveolar lavage fluid (BALF) cytology
Mouse lungs were sequentially lavaged three times with
0.5 ml physiological saline. Recovered aliquots of BALF
were pooled. BALF cells were pelleted by centrifugation
at 2000 rpm for 5 min. Cell differentials were deter-
mined with cytospin preparations stained with Wright–
Giemsa, and 200 cells were counted. The supernatant
was stored at −80 °C.
Analysis of lung histopathology
After BALF cytology, lungs were inflated with 10%
formalin and immersed in 10% formalin fixation solu-
tion. Paraffin-embedded lung sections were stained
with hematoxylin and eosin (H&E) for inflammatory
cell infiltration and proliferation of smooth muscle,
periodic acid-Schiff (PAS) for goblet cells and Masson
trichrome for airway fibrosis and collagen deposition.
An expert respiratory pathologist blinded to treatment
groups graded the extent of inflammation in the lungs
according to a semi-quantitative scoring system Scores
for inflammatory cell infiltration were 0, no inflammatory
infiltrations; 1, sporadic inflammatory cells; 2, more
maldistributed inflammatory cells, not gathered into
groups; 3, a large amount of inflammatory cells, uniformly
distributed but few gathered into groups; and 4, large
amount of inflammatory cells gathered into groups.
ELISA
The supernatant of BALF (1:10 diluted) was added to
96-well ELISA plates (100 μl/well) and incubated for
60 min at 37 °C. After washing, 1 μg/ml anti-PDCD5
antibody (100 μl/well) was added for incubation at 37 °C
for 60 min. After multiple washes, TMB solution
(100 μl/well) was added for incubation in the dark at
room temperature for 15 min. Color development was
stopped by adding 2 M H2SO4 (50 μl) and absorbance
was measured at OD 450 nm (OD450).
Immunohistochemistry (IHC)
Sections of 4 μm lung tissue were incubated with antibodies
for PDCD5 (1:300) and active caspase-3 (1:100) at 4 °C
overnight. IHC staining involved use of DAB (DAKO,
Carpinteria, CA, USA). The signal was recorded in
four grades by intensity of staining: 0, 1+, 2+ and 3+.
The percentages of PDCD5-positive cells or active
caspase-3 -positive cells were also recorded in four
categories: 1 (0–25%), 2 (26–50%), 3 (51–75%) and 4
(76–100%). The sum of the intensity and percentage
scores was used as the final staining score.
Statistical analysis
Data are presented as mean ± SD. One-way ANOVA was
used to compare multiple samples and Student’s inde-
pendent t test to compare two groups. Pearson correl-
ation coefficient (r) was calculated to assess correlations
between nonparametric and parametric data. P < 0.05
was considered statistically significant. Data were ana-
lyzed by using SPSS 13.0 and GraphPad Prism 5.0.
Table 1 Inflammatory cell profile in bronchoalveolar fluid (BALF) in mice with and without ovalbumin (OVA) challenge
Group Cell type count
Total cells (×104) Macrophages (×104) Eosinophils count (×104) Neutrophils (×104) Lymphocytes (×104)
Control (n = 8) 16.29 ± 4.72 15.54 ± 4.65 0 0.45 ± 0.22 0.31 ± 0.19
OVA challenge (n = 8) 33.47 ± 9.07* 21.99 ± 6.75* 4.09 ± 1.61* 3.85 ± 1.07* 3.54 ± 1.00*
Data are mean ± SD
*P < 0.05 compared with control







Control (n = 8) 0.09 ± 0.06 0.00 ± 0.00 0.19 ± 0.15
OVA challenge (n = 8) 2.38 ± 0.74** 1.81 ± 0.53** 1.31 ± 0.37**
Data are mean ± SD
**P < 0.01 compared with control
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Fig. 2 (See legend on next page.)
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Results
Respiratory function was markedly changed in OVA-
challenged mice
Compared with controls, OVA-challenged mice showed
lower PIF and PEF (2.26 ± 0.02 vs 2.62 ± 0.12 L/s, 4.65 ±
0.04 vs 6.21 ± 0.95 L/s, respectively, p < 0.05) (Fig. 1a).
The IP slope was higher in OVA-challenged mice than
controls (96.66 ± 2.88 vs 65.81 ± 7.07 mmHg/s, p < 0.05).
Airway inflammation and airway remodeling after OVA
sensitization
The total number of inflammatory cells in BALF was
higher in OVA-challenged mice than controls (33.47 ±
9.07 vs 16.29 ± 4.72 × 104, p < 0.05). Moreover, the counts
of macrophages, eosinophils, neutrophils and lymphocytes
were higher (p < 0.05) (Table 1, Fig. 1b).
The allergic asthma model showed increased inflamma-
tory cell infiltration in airways and pulmonary vasculature,
goblet-cell hyperplasia, smooth muscle cell proliferation,
peribronchial fibrosis and collagen level as compared with
controls (p < 0.01; Table 2, Fig. 2).
Elevated PDCD5 level in BALF and lung tissue after OVA
challenge
PDCD5 expression was increased in BALF of OVA-
challenged mice and its protein level in BALF was higher
(38.96 ± 9.96 vs 9.25 ± 7.76 μg/L, p < 0.05, Table 3). On
IHC, PDCD5 protein content was increased in airway
epithelial cells and inflammatory cells around airways
(Fig. 3). PDCD5 protein staining was greater in OVA-
challenged mice than controls (5.99 ± 0.52 vs 3.48 ± 0.35,
p < 0.01) (Table 3).
Correlation between PDCD5 expression and
clinicopathologic indexes
In BALF, PDCD5 level was positively correlated with
total number of cells collected (r = 0.781, p = 0.001,
n = 16) and total number of macrophages (r = 0.570,
p = 0.033, n = 16), eosinophils (r = 0.846, p = 0.000, n = 16),
neutrophils (r = 0.814, p = 0.000, n = 16) and lymphocytes
(r = 0.850, p = 0.000, n = 16). In lung tissue, PDCD5
staining intensity was negatively correlated with PIF
(r = −0.875, p = 0.000, n = 16) and PEF (r = −0.843, p =
0.001, n = 16) but positively with IP slope (r = 0.929,
p = 0.000, n = 16) (Fig. 4). A similar correlation was
found when analyzing PDCD5 level in BALF with
lung function (Additional file 1: Figure S1).
Correlation between active caspase-3 level and
clinicopathologic indexes
Active caspase-3 showed positive staining in airway
epithelial cells of bronchioles and bronchium of OVA-
challenged mice. Its protein was expressed mainly in mac-
rophages and some B lymphocytes and plasmocytes. Active
caspase-3 level was higher in OVA-challenged mice than
controls (5.875 ± 0.354 vs. 2.375 ± 0.518, p < 0.001). More-
over, PDCD5 and active caspase-3 levels were positively
correlated (r = 0.952, p = 0.000, n = 16) (Fig. 5).
Discussion
Our previous study demonstrated increased serum PDCD5
level in asthmatic patients, which was correlated with
(See figure on previous page.)
Fig. 2 Comparison of pathological changes in control and OVA-challenged mice. a Scores of pathological indices. b Representative lung sections
showing inflammatory cell infiltration and proliferation of smooth muscle cells with hematoxylin and eosin (HE) staining, goblet cell hyperplasia
with periodic acid-Schiff (PAS) staining, and airway fibrosis and collagen deposition around airway with Masson trichrome staining. Data
are mean ± SD. **P < 0.01 compared with control
Table 3 Programmed cell death 5 (PDCD5) level in BALF and
lung tissue with and without OVA challenge
PDCD5 Control (n = 8) OVA challenge (n = 8)
BALF (μg/L) 9.25 ± 7.76 38.96 ± 9.96*
Lung tissue 3.48 ± 0.35 5.99 ± 0.52**
Data are mean ± SD
*P < 0.05 compared with control, **P < 0.01 compared with control
Fig. 3 PDCD5 protein expression. a ELISA of PDCD5 protein level in
BALF. b IHC of PDCD5 protein content in lung tissue. Representative
PDCD5 IHC staining in lung sections of control (c) and asthmatic
mice (d). Data are mean ± SD (n = 16). *P < 0.05 compared with
control, **P < 0.01 compared with control
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clinical manifestations and lung function [23]. In the
present study, we successfully established a mouse model
of allergic asthma. This is the first report to investigate the
upregulation of PDCD5 in BALF and lung tissue of asth-
matic mice and to demonstrate that such upregulation
was correlated with number of inflammatory cells in
BALF and lung function as well as active caspase-3 level.
Moreover, activated caspase-3 level was increased and
correlated with PDCD5 level in asthma. These data
support our previous clinical findings and indicate that
PDCD5 may play a role in allergic asthma and its level
may be associated with asthma severity by regulating
apoptosis.
The asthmatic mouse model is commonly used to
study human asthma because of the similarities. OVA-
challenged mice show pathological and clinical features
similar to that observed in human allergic asthma. The
total number and proportion of eosinophils in BALF
was increased in our asthmatic mice. Lung function,
especially PEF, was decreased; as well, we found in-
flammatory cell infiltration, goblet cell hyperplasia,
increased mucus secretion and collagen deposition
around airways.
PDCD5 was first characterized as upregulated in cells
undergoing apoptosis [15]. Later its expression was found
downregulated in various tumors [25–28] but upregulated
in autoimmune diseases. PDCD5 was found involved in
some autoimmune diseases and inflammatory processes,
such as rheumatoid arthritis and psoriasis [29–31]. PDCD5
transgenic mice exhibited a systemic anti-inflammatory
condition in autoimmune encephalomyelitis mice [32].
Later the authors found the anti-inflammatory effects
of recombinant human PDCD5 (rhPDCD5) in a rat col-
lagen-induced arthritis model and provided the compre-
hensive assessment of immunosuppressive pathways of
rhPDCD [33]. However, few studies have investigated the
role of PDCD5 in asthma. In the present study, our results
imply a correlation between asthma and apoptosis and
Fig. 4 Correlation between PDCD5 expression and clinicopathologic characteristics. a-e Correlation between PDCD5 level and number of
inflammatory cells in BALF, (f-h) Correlation between PDCD5 level in lung tissues and lung function
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confirm that PDCD5 participates in airway inflammation
and airway remodeling of asthma; downregulated expres-
sion of PDCD5 could reflect the relief of airway inflamma-
tion and remodeling.
Asthma in humans is due to not just allergy. Our previ-
ous study of PDCD5 in asthma patients did not specify
whether asthmatic patients were allergic or not, whereas
the mouse model in this study is an allergic asthma model.
Considering the consistent correlation between PDCD5
expression and severity of asthma from clinical research
to animal models, although we cannot regard PDCD5 as a
potential biomarker for monitoring and controlling asth-
matic severity, PDCD5 may play a role in allergic asthma.
Moreover, we found increased PDCD5 protein level
in airway epithelium and inflammatory cells around
airways. PDCD5 could induce apoptosis of many kinds
of cells [34, 35]. Thus, with increased number of cells
involved in inflammation and remodeling, more PDCD5
was produced to inhibit the progression of inflammation
and remodeling. Accordingly, with reduced number of
cells involved in inflammation and remodeling, PDCD5
expression was reduced. However, further studies of the
underlying molecular mechanisms are required.
Caspases are a family of cysteine-dependent aspartate-
directed proteases that play essential roles in apoptosis,
necrosis, and inflammation [36]. There are two types of
apoptotic caspases: initiators (apical) and effectors (exe-
cutioner) [37]. Active effector caspases trigger the apop-
totic process [7]. Caspase-3 has long been recognized as
the key executioner caspase in apoptosis, and active
caspase-3 is an early marker of apoptosis [7–9]. To
further identify the correlation between asthma and
apoptosis, we measured the level of active caspase-3. In
agreement with previous studies, active caspase-3 pro-
tein was expressed mainly in epithelial cells and macro-
phages. In accordance with the increased expression of
PDCD5 in OVA-challenged mice, active caspase-3 level
was also increased in lung tissues of these mice. Several
studies have reported that PDCD5 can promote the
activation of caspase-3 [38–40]. Upregulated active
caspase-3 indicates increased cell apoptosis during the
development of asthma. Macrophages or bronchial
epithelial cells can recognize and remove apoptotic
eosinophils, so increased apoptotic epithelial cells or
macrophages may lead to airway remodeling and accu-
mulated eosinophils.
Zn is an important regulator of caspase-3 [41]. Truong-
Tran et al. found adverse effects of Zn deficiency on the re-
spiratory epithelium and a role for altered Zn homeostasis
and caspase upregulation in asthma [42]. However, further
study of the possible effect of a Zn-limited diet on caspase
upregulation in asthmatic mice is needed.
Fig. 5 Active caspase-3 protein expression. a IHC of active caspase-3 protein content in lung tissue, (b) Correlation between PDCD5 and active
caspase-3 level. Representative active caspase-3 IHC staining of lung sections of control (c) and OVA-challenged mice (d). Data are mean ± SD
(n = 16). ***p < 0.001 compared with control
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Conclusions
We found a correlation between PDCD5 expression and
severity of asthma in OVA-induced asthmatic mice.
PDCD5 may play a role in allergic asthma. Future studies
are required to determine the underlying mechanism.
Additional file
Additional file 1: Fig. S1. Correlation between PDCD5 level in BALF
and lung function. (TIF 40 kb)
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